Memantine for Lupus Brain Fog

What Did the Memantine Study Find in People With Lupus?

MedPage Today reported that memantine relieved cognitive dysfunction—often described as lupus brain fog—in people with systemic lupus erythematosus. Problems with attention, memory and mental processing can occur among the neuropsychiatric manifestations of lupus, although symptoms and underlying causes vary considerably between patients.

A statistically significant result from a small study should be considered an early efficacy signal rather than definitive evidence. Larger controlled trials are needed to determine the size and durability of any benefit, identify which patients are most likely to respond and establish whether improvements translate into better daily functioning.

Why Might an Alzheimer’s Medicine Help Lupus Brain Fog?

Memantine is an NMDA-receptor antagonist that modifies signaling involving glutamate, an important excitatory neurotransmitter. The FDA has approved it for moderate-to-severe dementia of the Alzheimer’s type, where it may provide modest symptomatic benefit but does not cure or reverse the underlying disease.

Lupus-related cognitive dysfunction can involve inflammatory, vascular, immune and psychological factors rather than one universal mechanism. A plausible neurological mechanism therefore does not prove that memantine will work across the broader lupus population; future studies must clarify whether benefits are linked to particular clinical features or disease pathways.

Should Patients Use Memantine for Lupus Cognitive Symptoms?

Using memantine specifically for lupus brain fog would currently be an off-label decision requiring individualized medical assessment. Its known adverse effects can include dizziness, headache, confusion and constipation, while reduced kidney function may require dosage adjustment because the medicine is substantially cleared through the kidneys.

Cognitive symptoms in someone with lupus also warrant evaluation for active disease, medication effects, depression, anxiety, fatigue, poor sleep and vascular risk factors. Sudden confusion, difficulty speaking, weakness, seizures or other acute neurological changes require urgent medical assessment rather than self-treatment with a cognitive medicine.